Prognostic value of serial B-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial)
O'Neill BP, Guerrero M, Thourani VH, Kodali S, Heldman A, Williams M, Xu K, Pichard A, Mack M, Babaliaros V, Herrmann HC, Webb J, Douglas PS, Leon MB, O'Neill WW. Prognostic Value of Serial B-Type Natriuretic Peptide Measurement in Transcatheter Aortic Valve Replacement (from the PARTNER Trial). Am J Cardiol. 2015;115(9):1265-1272.
The American journal of cardiology
B-type natriuretic peptide (BNP) levels have shown a correlation with outcomes in studies of aortic valve surgery. Results from multicenter trials of BNP in transcatheter aortic valve surgery (TAVR) are lacking. The aim of this study was to investigate the prognostic role of serial measurement of BNP in transfemoral TAVR. A total of 1,097 patients who underwent TAVR via transfemoral access were analyzed by tertile of baseline BNP. Of those, 933 with BNP levels at 30 days were divided into 2 groups on the basis of increases (334 patients) or decreases or no change (599 patients) in BNP compared with baseline. Patients in the low-tertile BNP group had a lower rate of death at 1 year than those in the higher tertile group (15.0% vs 23.0%, p
Medical Subject Headings
Aged; Aged, 80 and over; Aortic Valve Stenosis; Biomarkers; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Male; Natriuretic Peptide, Brain; Predictive Value of Tests; Transcatheter Aortic Valve Replacement; Treatment Outcome